DalsnaFinance › Analyst accuracy › JPMorgan › NGNE target
JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential
JPMorgan initiated coverage of Neurogene with an Overweight rating and set a price target of $60.00.
A fact about what JPMorgan published, as reported by Investing.com, not a recommendation from Dalsna Finance; JPMorgan is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.